Point-of-care in vitro diagnostic test for rapid detection and monitoring of bladder cancer. Provides doctors' office testing capability with high sensitivity for clinical decision-making in oncological patient management.
Manufactured by
Bromma, Sweden
IDL Diagnostics is a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics targets different patient groups in different parts of the world. With an organization that occupies the entire value chain from R D to manufacturing and marketing, we have the flexibility of a small company and the characteristics of a big company. It enables us to be a fast mover in the fast growing field of IVD-tests This is critical for us to be able deliver on our vision to be valuable and relevant diagnostic partner in oncology healthcare. Based on our proprietary technologies and our biomarkers, we develop tests that are clinically useful and economically viable, making us a valuable and relevant diagnostic partner for healthcare professionals. We provide rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, and easy to perform – all of which are important criteria for the healthcare and payer community. At IDL Diagnostics, we are proud that our diagnostic solutions can contribute to one of the three imperatives for reducing the burden of disease: diagnostics, therapeutics and vaccines. In the wake of covid-19, it is fair to say that diagnostics has been given a well-deserved place in the healthcare limelight. With a growing number of elderly people around the world in combination with an increase in the incidence of chronic diseases, the need for accurate diagnostics is essential. We create value for our shareholders by executing our strategy of increasing sales volumes in existing markets, obtaining market approvals in other prioritized markets, and continuously developing the next generation of IVD tests. With a pipeline that meets current and future demands, we stay relevant not only to patients, but to all our stakeholders. IDL Diagnostics was first listed in 2016 and our shares are traded on Stockholm Nasdaq First North.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Rapid Viral Detection Systems
United States · 1 relevant product
STRATEC/Diatron
Germany · 1 relevant product
Beijing SynsorBio Technology Co., Ltd
China · 1 relevant product
Nova Biomedical Corporation
United States · 1 relevant product
Wuhan YZY Medical Science and Technology Co.,Ltd.
China · 2 relevant products
Hangzhou Allsheng Instruments Co., Ltd.
China · 1 relevant product
Toda Pharma Sarl
France · 3 relevant products
Biosino Bio-Technology and Science Inc.
China · 1 relevant product
Fraunhofer-Institut für Mikrotechnik und Mikrosysteme IMM
Germany · 1 relevant product
Dutch Diagnostics B.V.
Netherlands · 1 relevant product
75 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →12 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 96 closest product alternatives
Rapid Viral Detection Systems · United States
Point-of-care liquid biopsy platform for rapid cancer detection with 99% accuracy and high sensitivity. Delivers non-invasive screening results in minutes, enabling early diagnosis across multiple cancer types at a lower cost than conventional test kits.
STRATEC/Diatron · Germany
In-vitro diagnostic test for detecting tumor markers and cancer-related antigens in blood and other biological samples. The test aids in cancer screening, diagnosis, and treatment monitoring.
Beijing SynsorBio Technology Co., Ltd · China
CRISPR-based molecular diagnostic test for tumor detection utilizing proprietary isothermal amplification and microfluidic integration. Enables rapid point-of-care testing with high sensitivity and specificity for oncology screening and monitoring applications.
Nova Biomedical Corporation · United States
Point-of-care diagnostic instrument for detecting kidney disease markers outside traditional hospital settings. Enables rapid assessment of renal function through blood or urine analysis, supporting early disease identification and patient monitoring in clinical and remote care environments.
Wuhan YZY Medical Science and Technology Co.,Ltd. · China
In vitro diagnostic test for identifying and quantifying cancer-related biomarkers. Supports oncology diagnosis, prognosis, and treatment monitoring.
Hangzhou Allsheng Instruments Co., Ltd. · China
Point-of-care testing system for molecular detection applications. Enables rapid on-site diagnosis with molecular-level precision for clinical or field testing.
Toda Pharma Sarl · France
Point-of-care diagnostic tests for identifying infectious diseases in clinical settings. These CE-marked solutions deliver reliable results within minutes to support infection prevention and patient management.
Biosino Bio-Technology and Science Inc. · China
In-vitro diagnostic products specifically developed for detection of multiple cancer types, enabling early identification and treatment planning. The product line supports clinical decision-making in oncology.
Fraunhofer-Institut für Mikrotechnik und Mikrosysteme IMM · Germany
Point-of-care testing device for rapid protein detection in clinical and laboratory settings. Enables decentralized diagnostic analysis with microsystem-based technology for improved workflow efficiency and faster patient results.
Dutch Diagnostics B.V. · Netherlands
A quality rapid test for bladder cancer detection. The test is CE marked and produced under strict supervision and quality regulations.
Randox Laboratories Ltd. · United Kingdom
Diagnostic tests and biomarkers for female bladder cancer detection and monitoring. These products support urological cancer screening and diagnosis.
Polymedco, Inc. · United States
A diagnostic test for the detection of recurrent bladder cancer, delivering results in only 5 minutes.
84 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products